Bohai Pharmaceuticals Group Announces Introduction of Five Pharmaceutical Products

New Products Significantly Expand Current Offering from 10 to 15 Products

YANTAI, China--(BUSINESS WIRE)--Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

“We are pleased to report this significant expansion of our product offering”

The new products, drawn from the stable of 29 products that Bohai is already licensed to manufacture, significantly expand Bohai’s pharmaceutical offering from 10 to 15 products. Three of the new products were introduced to the Chinese market in April 2010, with the remaining two products introduced in May 2010. In addition to the 15 TCM products now in production, Bohai holds the rights to produce 14 other TCM formulations in China.

"We are pleased to report this significant expansion of our product offering,” said Mr. Hongwei Qu, President and Chief Executive Officer of Bohai Pharmaceuticals. “Each of Bohai’s recently introduced products is specifically tailored to address a particular area of the body, ranging from stomach aches to chronic joint and back pain. In order to launch the products, a sales campaign was introduced to increase the general public’s awareness of these new offerings. As our sales initiatives take hold, we look forward to reporting on the progress of our expanded portfolio in fiscal 2011.”

Out of the five recently introduced products, three are prescription drugs and the remaining two are non-prescription, or Over-the-Counter (OTC) medicines. The new products are intended to supplement, but not diminish, Bohai’s sales strategies for it flagship offerings, Tongbi Capsules and Tablets and Lung Nourishing Cream. The company also indicated that initial sales of these products will not contribute materially to its June 30, 2010 year end results.

Mr. Qu continued, “In addition to this announcement, we look forward to bringing our US investors more detailed profile descriptions of these recently introduced products over the next several weeks, including in our forthcoming 10-K annual report. We believe our capital raise in January, combined with our expanded TCM portfolio and proactive sales initiatives will serve to drive our revenue and earnings potential in the new fiscal year.”

Bohai Pharmaceuticals Group recently became a US publicly listed company in early 2010, along with a concurrent $12 million private raise, and expects to achieve record levels of revenue and earnings for its fiscal year ending June 30, 2010 due to its corporate growth initiatives and expertise in China’s expanding pharmaceutical and Traditional Chinese Medicine (TCM) industries. The company is committed to establishing itself as a leading manufacturer and distributor of TCM throughout China’s major cities and rural areas. The company believes it is positioned to capitalize on the rapidly-growing demand for TCM products in China, which is anticipated to increase due to China’s rising middle class, increasing elderly population and Chinese government support.

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai’s medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai’s products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai’s lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, are eligible for reimbursement under China’s National Medical Insurance Program.

For additional information, please visit Bohai’s corporate website: www.bohaipharma.com.

Additional Information Relating to Bohai’s Trading Data

Due to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB), incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of otcmarkets.com, and Bohai Pharmaceuticals Group, Inc. makes no representation or warranty regarding the OTCQB market.

For real-time trading data for Bohai on the OTCQB market, including Level 2 quotes, please visit: www.otcmarkets.com/stock/boph/quote.

Cautionary Note Regarding Forward Looking Statements

This press release and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results (including, without limitation, results from marketing efforts and sales of Bohai’s new products discussed in this release) could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.